Your browser doesn't support javascript.
loading
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl, Mark; Blauvelt, Andrew; Paul, Carle; Sofen, Howard; Weglowska, Jolanta; Piguet, Vincent; Burge, Daniel; Rolleri, Robert; Drew, Janice; Peterson, Luke; Augustin, Matthias.
Afiliação
  • Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: lebwohl@aol.com.
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon.
  • Paul C; Paul Sabatier University, Toulouse, France.
  • Sofen H; David Geffen School of Medicine, University of California, Los Angeles, California.
  • Weglowska J; Niepubliczny Zaklad Opieki Zdrowotnej multiMedica, Wroclaw, Poland.
  • Piguet V; University Hospital of Wales, Cardiff University, Cardiff, United Kingdom; Women's College Hospital, University of Toronto, Toronto, Canada.
  • Burge D; Dermira Inc, Menlo Park, California.
  • Rolleri R; UCB Pharma, Raleigh, North Carolina.
  • Drew J; Dermira Inc, Menlo Park, California.
  • Peterson L; UCB Pharma, Raleigh, North Carolina.
  • Augustin M; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J Am Acad Dermatol ; 79(2): 266-276.e5, 2018 Aug.
Article em En | MEDLINE | ID: mdl-29660425
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Produtos Biológicos / Fator de Necrose Tumoral alfa / Fármacos Dermatológicos / Certolizumab Pegol Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Produtos Biológicos / Fator de Necrose Tumoral alfa / Fármacos Dermatológicos / Certolizumab Pegol Idioma: En Ano de publicação: 2018 Tipo de documento: Article